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Introduction
Takayasu arteritis (TA) is a chronic inflammatory disease 
that mainly affects large arteries such as the aorta and its 
major branches with an unknown etiopathogenesis [1, 2]. 
The inflammatory process of Takayasu’s arteritis causes 
thickening, narrowing or occlusion of the affected vessels 
and finally results in various symptoms. As well as mon-
etary considerations, patients are concerned about their 
quality of life. A study demonstrated that the quality of life 
of TA patients, including both physical and mental compo-
nents, was worse than that of age-matched, healthy patients 
[3]. Studies on the management of TA patients are rare, and 
oral glucocorticoid agents were recommended as first-line 
therapy [4]. However, many patients require large mainte-
nance steroid doses and are exposed to the risk of chronic 
toxicity [5]. Nearly, half of all patients will relapse during 
tapering and, consequently, will require additional immu-
nomodulating drugs, such as azathioprine, cyclophospha-
mide, and methotrexate [4]. Therefore, we should search 
for an optimum treatment to improve the therapeutic effect 
and to reduce disease activity so that the patients’ quality of 
life is improved.
In recent years, mycophenolate mofetil (MMF) has 
been widely used as a concomitant drug for TA, and some 
researchers have studied the application of MMF in TA 
patients in their countries. MMF may control the disease 
activity and allow for tapering of the steroid dosage [5, 6]. 
Nevertheless, to our knowledge, there is no published study 
assessing the explicit efficacy of treating TA with MMF 
combined with a steroid systematically. Thus, we per-
formed a systemic review and meta-analysis to evaluate the 
effectiveness of MMF in patients with TA.
Abstract The purpose of this study is to assess the 
effectiveness of mycophenolate mofetil (MMF) in treat-
ing Takayasu arteritis (TA) patients. Embase, Cochrane 
Library, Pubmed, Clinicaltrials. Gov and three Chinese lit-
erature databases (VIP, CNKI, WanFang) were searched; 
randomized-controlled trials and observational studies 
that compared the efficacy before and after treatment with 
MMF were included. The efficacy outcomes were disease 
activity, the erythrocyte sedimentation rate (ESR), C-reac-
tive protein (CRP) values and steroid dosage. The results 
were expressed as mean differences with 95% confidence 
intervals. Compared with the baseline, there were signifi-
cant reductions in the ESR (−14.92 [25.35, −4.48]), CRP 
values (−12.99 [−23.29, −2.68]) and the steroid dosage 
(−17.64 [−24.89, −10.4]) after the addition of MMF, and 
the disease tended to stabilize. Therefore, MMF might be 
an alternative immunosuppressive drug for TA for the con-
trol of disease activity and to taper the steroid dosage.
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We conducted a meta-analysis following the meth-
ods specified in the Cochrane Handbook for Systematic 
Reviews of Intervention [7]. Outcome measures included 
disease activity (including imaging examinations), the 
erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP) values and the steroid dosage.
Data sources
Eligible trials were identified through electronic searches 
(conducted by two independent reviewers, D. D. and Y. 
W.). Searches were performed in Embase, Cochrane 
Library, Pubmed, Clinicaltrials. Gov and three Chinese 
literature databases (VIP, CNKI, WanFang) from their 
inception until September 2015. The search was lim-
ited to English or Chinese articles. The search strategy 
is shown in Table  S1. In addition, the reference lists of 
eligible studies were also scanned to identify additional 
relevant studies.
Study selection
The electronic search results were imported to a manage-
ment software, and the duplicate results were deleted. 
Two reviewers (D. D. and Y. W.) independently screened 
all titles and abstracts for eligible studies. Studies were 
included if they met the following criteria: (1) TA was 
diagnosed unequivocally; (2) MMF was used for treat-
ment; (3) the study design was a randomized controlled 
trial (RCT) or observational study; (4) the study included 
one of the predefined outcome measures; and (5) the 
study was published in English or Chinese.
Data extraction
Two authors extracted data independently (D. D. and Y. 
W.). Any dispute was settled by discussion or by a third 
investigator. Study characteristics were extracted from 
each study, including first author identification, year of 
publication, sample size, study location, study design, 
sex, age, duration of TA, duration of MMF therapy, and 
other concomitant drugs before MMF.
Laboratory parameters (e.g., the ESR value, CRP 
value, steroid dose, and disease activity) before the first 
introduction of MMF were extracted as baseline values 
(before MMF) and were compared to the same parame-
ters extracted at the end of the study (after MMF).
Any drop in the ESR or/and CRP values was consid-
ered as efficacy due to the therapy. If patients did not 
relapse or the disease was stable during the steroid taper-
ing, we also considered the treatment to be effective.
Quality assessment
The Newcastle–Ottawa Scale (NOS) was adopted to evalu-
ate the quality of the included studies [8].
Data analysis
The meta-analysis was accomplished by RevMan 5.1 
(Cochrane IMS). A fixed effects model was selected and 
Cochrane Q χ² and I² statistics were used to estimate the 
heterogeneity among studies. I² values of over 25%, 50% 
and 75% represent low, moderate and high heterogeneity, 
respectively [9, 10]. p values of 0.05 were used to deter-
mine statistical significance. The results were calculated 
using the Mantel–Haenzsel method and are expressed as 
mean differences (MD) for continuous outcomes with 95% 
confidence intervals.
A sensitivity analysis was performed to test the robust-
ness of the main results. We re-analyzed the data using a 
random effects model. The results for the sensitivity analy-
sis are only reported if the conclusions differed.
Results
Literature search
The study selection process for inclusion is shown in Fig. 1. 
The electronic searches identified 1524 potentially relevant 
articles. After initially excluding duplicates and the initial 
screening, 17 relevant articles were selected, and 15 arti-
cles were excluded for the reasons shown in Table  S2. A 
total of 2 articles involving 31 patients were included in the 
meta-analysis. We did not obtain any additional studies by 
scanning the reference lists of eligible studies.
Study characteristics
The characteristics of the included studies are summarized 
in Table 1. Thirty-one patients diagnosed with TA accord-
ing to the American College of Rheumatology (ACR) 
criteria were involved [11]. Of these, two patients aban-
doned the studies due to their severe adverse events related 
to MMF [5, 6]. Fifteen patients had received at least one 
immunosuppressive drug before the administration of 
MMF (12 azathioprine, 4 methotrexate, and 1 chloram-
bucil). Because these two studies used different criteria to 




A summary of meta-analysis for efficacy is shown in 
Table 2; forest plots are shown in Fig. 2. The raw data are 
shown in Table  S3. We performed a fixed effects meta-
analysis including 31 patients assigned to the “before” 
MMF group and 29 patients assigned to the “after” MMF 
group.
Fig. 1  Flow chart of study 
selection
Table 1  Characteristics of the included studies
 TA Takayasu’s arteritis, MMF mycophenolate mofetil
 aMycophenolate mofetil as an alternative immunosuppressive drug accompanying steroids in controlling TA disease activity
 bOne patient was not used to evaluate efficacy because of a skin rash, and 11 patients were on steroids alone before MMF
 cOne patient was not used to evaluate efficacy due to a severe headache, and five patients were on steroids alone before MMF
 dOne received methotrexate + azathioprine
 eOne received chlorambucil + methotrexate





Age (years) TA duration 
(months)
MMF  therapya 
(months)
Other immunosup-
pressive drugs before 
MMF (n)
Goel et al. [5] India, retrospective 21b (2/19) Mean ± SD: 
31.9 ± 13.8
Mean ± SD: 
35.5 ± 28.4
Range:1–120
Mean ± SD: 
9.6 ± 6.4
Azathioprine (10)
Shinjo et al. [6] Brazil, prospective 10c (3/7) Mean ± SD: 
29.9 ± 8.9
Range: 18–40
Mean ± SD: 
57.5 ± 65.8





Table 2  A summary of the meta-analysis for efficacy
Lab parameter No. of studies con-
tributing data
MD (95%) No. of participants of 
experimental group
No. of participants of 
control group
I² (%) p
ESR 2 −14.92 [25.35, −4.48] 29 31 5 0.005
CRP 2 −12.99 [−23.29, −2.68] 29 31 0 0.01




Both studies reported a great reduction in the ESR from 
baseline to the end of the study period, with a mean differ-
ence of −14.92 (95% CI −25.35 to −4.48, p = 0.005). This 
result is shown in Fig. 2a. No significant heterogeneity was 
found in the analysis (I² = 5%, p = 0.31).
Steroid dosage
Both studies reported significant decreases in the steroid 
dosage from baseline to the end of the study. This result is 
shown in Fig. 2b. The mean difference was −17.64 (95% CI 
−24.89 to −10.4, p < 0.00001). Insignificant heterogeneity 
was found among the included studies (I² = 0%, P = 0.82).
C-reactive protein values
The mean difference of the CRP values was −12.99 (95% 
CI −23.29 to −2.68, p = 0.01). This result is shown in 
Fig. 2c. There was no significant heterogeneity among the 
included studies (I² = 0%, p = 0.94).
Disease activity
Goel et  al. [5] assessed disease activity with Indian 
Takayasu’s arteritis activity score (ITAS) [12] scoring 
system, while Shinjo et al. [6] used the National Institutes 
of Health (NIH) [11] criteria. Regardless of which evalu-
ation standard was used, both studies reported significant 
improvement in the disease activity, and all patients were 
stable at the end of the study, except two patients who 
dropped out of the studies.
The quality assessment of the included studies
Using the 9-point scoring system, the scores of the included 
studies were 8 and 9. The results of the specific quality 
scores from the NOS system are summarized in Table S4.
Discussion
Primary guidelines recommend immunosuppressive 
agents, such as azathioprine, cyclophosphamide, and 
Fig. 2  Forest plots
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methotrexate as second-line agents [4]. Nevertheless, the 
long-term administration of such drugs can cause seri-
ous side effects. For example, cyclophosphamide can 
cause cystitis, bladder cancer and infertility (especially 
in TA patients) [13]. Although less toxic than cyclophos-
phamide, methotrexate can cause severe bone marrow 
depression, which may lead to life-threatening infections 
or spontaneous hemorrhage. These drugs are only to be 
used carefully when withdrawal from steroids is difficult 
[14]. Therefore, it is necessary to identify alternative 
immunosuppressants with lower hepatotoxicity, nephro-
toxicity and other severe side effects. Recently, MMF 
was used to treat TA patients who did not tolerate aza-
thioprine, cyclophosphamide, or methotrexate [1, 2, 5, 6, 
15–18], and it achieved a favorable response [2, 5, 6].
Although there are no established specific biologi-
cal markers to estimate disease, patients with TA often 
present with higher ESRs and CRP values [19]. There-
fore, reduced ESRs and CRP values seem to be a good 
indicator of disease remission. The results of the present 
meta-analysis demonstrated that MMF is effective in con-
trolling disease activity and tapering the steroid dosage. 
Moreover, MMF could significantly decrease the ESR 
and CRP values. Similar results were reported by Erica 
Daina [2]. A sensitivity analysis further confirmed that 
our findings were robust (results shown in Table S5).
However, our study has several limitations. First, 
although we searched widely, there were only two obser-
vational studies included, and the sample size was small 
(only included 31 patients). Second, because of the lack 
of data, imaging examination results could not be pooled, 
although this is an important measurement of long-term 
efficacy. Third, the use of observational studies in a meta-
analysis is liable to the biases and confounding factors 
that are inherent in the original studies.
In conclusion, MMF might be an alternative immu-
nosuppressive drug for TA incontrolling disease activ-
ity and tapering the steroid dosage. However, further 
research with longer follow-up periods and more partici-
pants is needed.
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